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IMPACT Statement: We certify that this work is novel of recent novel clinical research. 41 
The potential impact of this research on clinical care or health policy includes the following: (1) 42 
consideration on whether exercise should be offered to people with mild to moderate dementia; (2) 43 
suggestion that not all people with mild to moderate dementia have comparable clinical outcomes 44 
to exercise interventions; and (3) provides evidence for stratification of exercise prescription for 45 
people with mild to moderate dementia. 46 
 47 




OBJECTIVES: To estimate whether baseline participant variables were able to moderate the effect of 51 
an exercise intervention on cognition in patients with mild to moderate dementia.  52 
 53 
DESIGN: Subgroup analysis of a multi-centre, pragmatic, randomised controlled trial. 54 
 55 
SETTING: Community-based gym/rehabilitation centres 56 
 57 
PARTICIPANTS: 494 community-dwelling participants with mild to moderate dementia. 58 
 59 
INTERVENTION: Participants were randomised to a moderate- to high-intensity aerobic and strength 60 
exercise programme or a usual care control group. Experimental group participants attended twice-61 
weekly gym sessions for 60 to 90 minutes duration for four months. Participants were prescribed 62 
home exercises for one additional hour per week during the supervised period, and 150 minutes each 63 
week after the supervised period.  64 
 65 
MEASUREMENTS: Multi-level regression model analyses were undertaken to identify individual 66 
moderators of cognitive function measured through the ADAS-Cog at 12 months.  67 
 68 
RESULTS: When tested for a formal interaction effect, only cognitive function assessed by the baseline 69 
number cancellation test, demonstrated a statistically significant interaction effect (-2.7 points; 95% 70 
confidence interval: -5.14 to -0.21). 71 
 72 
CONCLUSIONS: People with  worse number cancellation test scores may experience greater 73 
progression of cognitive decline in response to a moderate- to high-intensity exercise programme. 74 
Further analyses to examine whether these findings can be replicated in planned, sufficiently-powered 75 
analyses are indicated. 76 
 77 




Dementia is a global health and social care challenge. Approximately 50 million people worldwide 81 
have dementia.[1] No effective interventions are available which cure or directly modify the course of 82 
dementia.[2] The hypothesis that aerobic and strengthening exercise may slow cognitive impairment 83 
in dementia has gained widespread popularity. Studies describe plausible mechanisms using 84 
mammalian models.[3] Recent systematic reviews of trials of exercise training in people with 85 
dementia present conflicting findings.[4,5] These confirm the multiplicity of small studies of low 86 
methodological quality, limited duration of follow-up and high unexplained heterogeneity in findings.  87 
We recently reported a randomised controlled trial investigating the effect of a moderate- to high-88 
intensity aerobic and strength exercise training programme on cognitive impairment at 12 months in 89 
494 community-dwelling people with mild to moderate dementia.[6] This targeted known mechanistic 90 
pathways in vascular and Alzheimer’s type dementia. At 12-month follow-up, the mean Alzheimer 91 
Disease Assessment Scale Cognitive (ADAS-Cog) score increased to 25·2 (standard deviation (SD): 12·3) 92 
in the exercise group and 23·8 (SD: 10·4) in the usual care group (indicating worse cognitive 93 
impairment in the exercise group).[6] A priori subgroup analyses found no evidence for gender, 94 
standardised mini-mental state examination (sMMSE) score, prior mobility or type of dementia 95 
modifying cognitive function.[6] However, other theoretically plausible subgroups were not tested. 96 
Given these results suggest that the intervention could adversely affect cognitive function, this 97 
analysis aimed to estimate whether baseline participant variables were able to moderate the effect 98 





The design, intervention and main analysis results for the DAPA trial have been reported 104 
elsewhere.[6,7] 105 
 106 
Participants and randomisation 107 
In brief, 494 community-dwelling people with mild to moderate dementia were recruited from 15 108 
regions across England. People were eligible if they had a clinically-confirmed diagnosis of dementia 109 
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according to the Diagnostic and Statistical Manual 4th Edition (DSM-IV)[8] and a sMMSE of greater 110 




The experimental intervention was a moderate- to high-intensity aerobic and strength exercise 115 
programme. Participants attended twice-weekly gym sessions for 60-90 minutes in duration for four 116 
months. Participants were prescribed home exercises for one additional hour per week during the 117 
supervised period, and thereafter, prescribed a more frequent home-based programme with a target 118 
of 150 minutes per week unsupervised physical activity or exercise. Behavioural strategies were used 119 
to promote adherence during the supervised programme.[10] Telephone-administered motivational 120 
interviews were used to promote adherence after the supervised programme.  121 
 122 
Participants in the control group received usual care. This included counselling for carers and families, 123 
a clinical assessment, prescription of symptomatic treatments and brief advice about physical activity.  124 
 125 
Outcome Measure 126 
 127 
Data were collected at baseline, six and 12-months. The outcome of interest in the main trial was the 128 
ADAS-Cog at 12 months.[11] This is an 11-item, participant-rated scale, scored 0-70; higher scores 129 
indicate worse cognitive impairment. It includes praxis, memory, language, number cancellation and 130 
maze test subscales. Trained interviewers administered the cognitive function measures in 131 
participant’s homes. A four-point change is regarded a clinically important within-person change at 132 
six months,[12] and a seven-point change at 18 months.[13] A between-group difference of two to 133 
three points is regarded as a worthwhile target for clinical trials.[14] For the purposes of these sub-134 
group analyses, the primary outcome was change from baseline to 12 months.  135 
 136 
Statistical Analyses  137 
We undertook sub-group analyses to identify groups of participants who may have responded better 138 
or worse to the exercise intervention. To maintain acceptable statistical power, we selected only pre-139 
randomisation variables where there were data for a minimum of 50% of participants in the exercise 140 
intervention cohort (i.e. 164).[15] Baseline variables which met this criteria were: age; participant 141 
living arrangement (alone/with others); number of medications prescribed; baseline ADAS praxis, 142 
memory and language subscales and the number cancellation test; EQ-5D-3L health-related quality of 143 
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life (HRQOL) (higher scores indicate worse health state; participant-rated);[16] Quality of Life 144 
Alzheimer’s Disease (QoL-AD) scale (scored 13-52, higher scores indicating better perceived quality of 145 
life; participant-rated);[17] the Neuropsychiatric Index (NPI) (scored 0-144, higher scores indicating 146 
increased behavioural and psychological symptoms; carer-rated);[18] and the Bristol Activities of Daily 147 
Living (BADL) Index (scored 0-60, higher scores indicating greater impairment; carer-rated).[19]   148 
We used bar charts to visualise the dispersal of change in ADAS-Cog from baseline to 12-month follow-149 
up across both groups. We estimated treatment effects using change from baseline (baseline minus 150 
follow-up). To ensure that baseline differences did not influence analyses, we adjusted the models for 151 
the baseline variable. As there is no published guidance on relevant cut-points for the variables of 152 
interest, we used a median cut-point.[20]  153 
To assess for sub-group effects, we fitted multi-level regression models with an interaction term 154 
(treatment by subgroup interaction) while adjusting for age, gender, baseline of the dependent 155 
variable and baseline sMMSE. Region was included as a random-effect. We also undertook complier 156 
average causal effect (CACE) analyses to determine whether there was any treatment effect 157 
modification on the primary outcome for those who complied with treatment. Compliance was 158 
defined a priori as attending 22 out of a maximum 30 group sessions (75%). The sub-group effect 159 
estimate, 95% confidence interval (CI) and P-value were reported for each analysis. 160 
 161 
Data were imputed using recognized item-level multiple imputation techniques for the primary 162 
outcome (ADAS-Cog).[21] No missing data was imputed for any other variable.  163 
 164 
All statistical tests were two-sided. Statistical significance was assessed at the five percent level. All 165 





Cohort Characteristics 171 
From 494 participants randomised, data were available for the primary outcome at 12 months for 172 
137/165 (83%) of usual care and 281/329 (85%) of exercise group. Baseline demographic and clinical 173 
characteristics for the trial cohort are presented in Table 1. These are presented for each subgroup by 174 
variable in Table 2.  175 
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Dispersal of ADAS-Cog Results 176 
Figure 1 illustrates the change in total ADAS-Cog score from baseline to 12 months for each group. 177 
There was a positive change (improved cognitive function) in 49/137 participants (36%) of the usual 178 
care group, and 80/281 participants (29%) of the exercise group. There was a negative change 179 
(cognitive decline) in 86/137 participants (63%) of the usual care group, and 198/281 participants 180 
(71%) of the exercise intervention group.  181 
Principal Analysis 182 
When tested for a formal interaction effect, only cognitive function assessed by the baseline number 183 
cancellation test demonstrated a statistically significant interaction effect (-2.7 points; 95% CI: -5.14 184 
to -0.21; P=0.03). This remained present as the only variable with an interaction effect in the CACE 185 
analysis (-3.7 points; 95% CI: -7.23 to -0.21; P=0.04) (Table 2). There was no evidence of treatment 186 
modification for all other variables (Table 2). 187 
Inspection of within-strata changes suggest that cognitive decline was greater for eight variables 188 
(Table 2). Cognitive decline was greater in those aged over 78 years (-1.7 points; 95% CI: -3.41 to -189 
0.04), those with greater dementia-related behaviours (NPI greater 8 points) at baseline (-2.6 points; 190 
95% CI: -4.64 to -0.53) and reduced activities of daily living with a BADLs score of greater than 11 191 
points (-2.2 points; 95% CI: -4.27 to -0.06). Cognitive decline was greater for those who lived with 192 
others (-1.6 points; 95% CI: -2.96 to -0.24). People with worse cognitive function at baseline in terms 193 
of overall function (ADAS-Cog total score greater than 20 points) and all sub-scales (language (greater 194 
2 points), memory (greater 17 points), praxis (greater than 1 point) and number cancellation (greater 195 




This exploratory analysis has identified that participants with worse number cancellation test scores 200 
at randomisation, may experience greater progression of cognitive decline in response to a moderate- 201 
to high-intensity exercise programme. No other variable moderated participant response to 202 
treatment. Though the within-strata effects illustrate that those who underwent the exercise 203 
intervention demonstrated greater cognitive decline, these changes were  small. Due to the nature of 204 
exploratory analyses, these findings should be viewed with caution before replicating with sufficiently 205 
powered cohorts. 206 
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Whilst previous systematic reviews have concluded that exercise may have limited impact on altering 207 
cognitive performance for people with cognitive impairment per se,[22,23] this subgroup analysis 208 
indicated that this may not be the case for everyone. The finding that people with poorer number 209 
cancellation test score may experience greater progression of cognitive decline offers a signals that 210 
exercise may ‘harm’ some individuals. However, physical activity is advocated for older people with 211 
and without cognitive impairment, for a variety of health effects.[6,24]  It is therefore imperative that 212 
the results of this subgroup analysis are rigorously explored before consideration is made to change 213 
physical activity recommendations for people with mild to moderate dementia.  214 
Only pre-randomisation number cancellation test demonstrated an interaction effect with cognitive 215 
outcome. No other measures of cognitive impairment demonstrated such an interaction effect after 216 
exercise. This emphasises that the ADAS-Cog measures impairment in multiple cognitive domains 217 
across the subscales.[25] There is no clear reason why only a number cancellation test would predict 218 
greater cognitive decline following an exercise programme. It may be that number cancellation test 219 
demands a higher attentional load, particular in relation to selective attention in visuo-spatial 220 
memory, compared to the other tests.[26] However Halloway et al’s[27] previous assessment of the 221 
interaction between physical activity and cognitive activity, based on 742 older adults in the USA, 222 
suggests that any interaction may be attributed to memory rather than perceptual speed or 223 
visuospatial ability. Given this uncertainty, further research to understand why number cancellation 224 
test score should differ to other domains of cognitive function is warranted.  225 
The results of the CACE analysis indicate that compliance to the exercise programme was not 226 
associated with cognitive outcomes. It was not the purpose of this trial to assess the association 227 
between exercise dose-response and outcome. Previous literature has focused on the relationship 228 
between exercise intensity and outcome. This suggests that moderate- to high-intensity exercise is 229 
more effective at improving cognitive outcomes compared to lower-intensity exercise.[28] This is 230 
based on the principle that moderate- to high-intensity exercise drives synthesis and accumulation of 231 
neuroactive metabolites including myokines and ketone bodies, to enhance brain-derived 232 
neurotrophic factor expression.[29] However, it remains unclear whether there is a threshold related 233 
to frequency of exercise and outcome for people with mild or moderate cognitive impairment.[30]  234 
This analysis presented with three key limitations. Firstly, this analysis was not powered for these 235 
exploratory subgroup analyses. Brookes et al[15] recommend that sample sizes should be up to four 236 
times larger to power an interaction test within a subgroup analysis. Furthermore the unequal group 237 
allocation adopted in this trial compounded the issue of power for these analyses. Therefore, as with 238 
any subgroup analysis, the results should be interpreted with caution and the findings considered as 239 
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hypotheses. Secondly, data on exercise compliance and fidelity of the intervention was based on 240 
treatment logs and self-reported diaries. Whilst previously reported as a useful indicator,[31] it 241 
remains unclear to what extent exercise adherence and specifically the degree of exertion undertaken 242 
within exercise regimes, was met. Finally, the NPI could only be completed if the carer was a resident 243 
carer i.e. lived with the participant or if the carer was a non-resident but provided 16 or more hours 244 
of care per week, and had knowledge of night-time behaviours. Accordingly there was fewer data for 245 




This exploratory analysis indicates that people with poorer number cancellation scores at baseline had 250 
greater cognitive decline after a moderate- to high-intensity exercise programme. The differences 251 
were small over the time period assessed. Further analyses are indicated to examine whether these 252 




Acknowledgements: Members of the DAPA trial team (S Alleyne, S Hennings, F Griffiths, S 257 
Bridgewater, E Eyre, S Finnegan, L Hall, P Hall, H Johnson, G Kaur, L Langdon, S Lyle, J Lowe, S Mathews, 258 
J Millichap, J Nussbaum, I On-kar, C Ritchie, V Russell, G Scott, S Shore, K Spanjers, L Stonehewer, M 259 
Thorogood, J Todd, A Ullah, H Waters, L Woods, E Withers, P Zeh, A Bond, D Brown, C Byrne, R 260 
McShane, N Thomas, J Thompson, C Dransfield, F Le Frenais, C Hall, O Rye, R Carson, M Clarke, H Eaton, 261 
H Ellis, A Farrand, S Gardner, C Harducas, L Rigby, J Wilson, L Hill, L Johnson, L Lord, L Johnson, T 262 
Qassam, S Sadier, A Shipman, L South, J Statham, J Tomkins, D Weaver, B Coope, D Craddock, A Johal, 263 
J Lee, J Lindsay, J Tucker, R Vanderputt, V Cross, G Glithens-Mather, L Martin, C O’Reilly, E Rogers, R 264 
Sheridan, K Birtwell, J Brooke, A Davis, C Hinze, S Hussain, A Kennedy, H Mistry, R Noble, R Norton, E 265 
Oughton, V Sherwin, P Tinker, D Glancey, H Karrin, M Marudkar, G Borley, T Crisp, P Koranteng, A 266 
Lovesy, S Vogel, B Browne, L Colbourn, A Feast, E Hanratty, R Legerd, R Niland-Smith, T Sullivan, T 267 
Sullivan, A Streater, H St Roas, M Anderton, R Blake, K Brown, S Marriott, S Simpson, A Thornhill, L 268 
Colbourn, F Dawe, T Kuruvilla, L Moore, R Niland-Smith, M Phillips, G Riley, and A Uthup).  269 
 270 
 10 
Funding: The DAPA trial was funded by the National Institute of Health Research Health Technology 271 
Assessment Programme (NIHR HTA), project number 09/80/04. The funder has no role in the trial 272 
design; collection, management, analysis or interpretation of data; writing of reports and submission 273 
for publication. We developed this article in association with the NIHR Collaboration for Leadership in 274 
Applied Health Research & Care (CLAHRC) Oxford, UK, and the NIHR Oxford Musculoskeletal 275 
Biomedical Research Unit (SL, TS). The views and opinions expressed therein are those of the authors 276 
and do not necessarily reflect those of the Health Technology Assessment programme, NIHR, National 277 
Health Service, or the UK Department of Health and Social Care. HL is funded by the Australian 278 
National Health and Medical Research Council (grant no. APP1126767) 279 
 280 
Trial Registration: ISRCTN32612072 281 
Ethical Approval: NRES committee South West – Frenchay (REC number 11/SW/0232). 282 
Conflict of interest statement: All authors declare no conflict of interests in relation to this work.  283 
Author Contributions: 284 
1) Substantial contributions to conception and design: TS, DM, HL, SD, SF, BF, VPN, BS, SEL 285 
2) Acquisition of data: DM, HL, SEL 286 
3) Analysis and interpretation of data: TS, DM, HL, BF, BS, SEL 287 
4) Drafting the article: TS, DM, HL, BF, SEL 288 
5) Revising it critically for important intellectual content: TS, DM, HL, SD, SF, BF, VPN, BS, SEL 289 
6) Final approval of the version to be published: TS, DM, HL, SD, SF, BF, VPN, BS, SEL 290 
7) Guarantor: TS  291 
 292 
Sponsors: Role: None. 293 
 294 





1. Prince M, Comas-Herrera A, Knapp M, et al. World Alzheimer Report 2016. London, UK, 299 
Alzheimer's Disease International, 2016.  300 
 301 
2. Powell T. Health Policy and Dementia. Curr Psychiatry Rep 2018;20:4.  302 
 303 
3. Moore KM, Girens RE, Larson SK, et al. A spectrum of exercise training reduces soluble Aβ in 304 
a dose-dependent manner in a mousemodel of Alzheimer's disease. Neurobiol Dis 2016;85:218-24. 305 
 306 
4. Frederiksen KS, Gjerum L, Waldemar G, et al. Physical activity as a moderator of Alzheimer 307 
pathology: a systematic review of observational studies. Curr Alzheimer Res 2019;16:362-78.  308 
 309 
5. Dyer SM, Harrison SL, Laver K, et al. An overview of systematic reviews of pharmacological 310 
and non-pharmacological interventions for the treatment of behavioral and psychological symptoms 311 
of dementia. Int Psychogeriatr 2018;30:295-309.  312 
 313 
6. Lamb SE, Sheehan B, Atherton N, et al. Dementia And Physical Activity (DAPA) trial of 314 
moderate to high intensity exercise training for people with dementia: randomised controlled trial. 315 
BMJ 2018;361:k1675. 316 
 317 
7. Atherton N, Bridle C, Brown D, et al. Dementia and Physical Activity (DAPA) - 318 
an exercise intervention to improve cognition in people with mild to moderate dementia: study 319 
protocol for a randomized controlled trial. Trials 2016;17:165.  320 
 321 
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders 322 
(DSM-5®). American Psychiatric Publishing, 2013. 323 
 324 
9. Vertesi A, Lever JA, Molloy DW, et al. Standardized Mini-Mental State Examination. Use and 325 
interpretation. Cam Fam Physician 2001;47:2018-23. 326 
 327 
 12 
10. Brown D, Spanjers K, Atherton N, et al. Development of an exercise intervention to improve 328 
cognition in people with mild to moderate dementia: Dementia And Physical Activity (DAPA) Trial, 329 
registration ISRCTN32612072. Physiotherapy. 2015;101:126-34. 330 
 331 
11. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in 332 
clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that 333 
broaden its scope. Alz Dis Assoc Dis 1997;11:13-21.  334 
 335 
12. Rockwood K, Fay S, Gorman M. The ADAS-cog and clinically meaningful change in the VISTA 336 
clinical trial of galantamine for Alzheimer's disease. Int J Geriatr Psychiatry 2010;25:191-201. 337 
 338 
13. Vellas B, Andrieu S, Cantet C, et al. Long-term changes in ADAS-cog: what is clinically 339 
relevant for disease modifying trials in Alzheimer? J Nutr Health Aging 2007;11:338-41. 340 
 341 
14. Tak EC, van Uffelen JG, Paw MJ, et al. Adherence to exercise programs and determinants of 342 
maintenance in older adults with mild cognitive impairment. J Aging Phys Act 2012;20:32-46.  343 
 344 
15. Brookes ST, Whitley E, Peters TJ, et al. Subgroup analyses in randomised controlled trials: 345 
quantifying the risks of false-positives and false-negatives. Health Technol Assess 2001;5:1-56. 346 
 347 
16. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. 348 
Health Policy 1990;16:199-208. 349 
 350 
17. Logsdon RG, Gibbons LE, McCurry SM, et al. Assessing quality of life in older adults with 351 
cognitive impairment. Psychosom Med 2002;64:510–9. 352 
 353 
18. Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory. Comprehensive 354 
assessment of psychopathology in dementia. Neurology 1994;44:2308–14. 355 
 356 
19. Bucks RS, Ashworth DL, Wilcock GK, et al. Assessment of activities of daily living in dementia: 357 
development of the Bristol Activities of Daily Living Scale. Age and Ageing 1996;25:113-20. 358 
 359 
20. Altman DG, Royston P. The cost of dichotomous continuous variables. BMJ 2006;87:9-23. 360 
 361 
 13 
21. Little RJA, Rubin  DB. Statistical Analysis with Missing Data. John Wiley & Sons, Inc, 1986 362 
 363 
22. Lam FM, Huang MZ, Liao LR, et al. Physical exercise improves strength, balance, mobility, 364 
and endurance in people with cognitive impairment and dementia: a systematic review. J Physiother 365 
2018;64:4-15. 366 
 367 
23. Forbes D, Forbes SC, Blake CM, et al. Exercise programs for people with dementia. Cochrane 368 
Database Syst Rev 2015;4:CD006489. 369 
 370 
24. World Health Organisation. Physical activity and adults. Available at: 371 
https://www.who.int/dietphysicalactivity/factsheet_adults/en/. Accessed on: 03 April 2020 372 
 373 
25. Verma N, Beretvas SN, Pascual B, et al. New scoring methodology improves the sensitivity of 374 
the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials. Alzheimers 375 
Res Ther 2015;7:64. 376 
 377 
26. Della Sala S, Laiacona M, Spinnler H, Ubezio C. A cancellation test: 378 
its reliability in assessing attentional deficits in Alzheimer's disease. Psychol Med 1992;22:885-901. 379 
 380 
27. Halloway S, Schoeny ME, Wilbur J, et al. Interactive effects of physical activity and cognitive 381 
activity on cognition in older adults without mild cognitive impairment or dementia. J Aging Health 382 
2019; In Press. 383 
 384 
28. Koščak Tivadar B.  Physical activity improves cognition: possible explanations. 385 
Biogerontology 2017;18:477-83. 386 
 387 
29. Wang R, Holsinger RMD. Exercise-induced brain-derived neurotrophic factor expression: 388 
Therapeutic implications for Alzheimer's dementia. Ageing Res Rev 2018;48:109-21. 389 
 390 
30. Olanrewaju O, Kelly S, Cowan A, et al. Physical Activity in Community Dwelling Older People: 391 
A Systematic Review of Reviews of Interventions and Context. PLoS One 2016;11:e0168614  392 
 393 
31. Yeom HA, Keller C, et al. Interventions for promoting mobility in community-dwelling older 394 
adults. J Am Acad Nurse Pract 2009;21:95-100.  395 
  396 
 14 
FIGURE AND TABLE LEGENDS 397 
 398 
 399 
Table 1: Baseline demographic and clinical characteristics of all randomised participants. 400 
 401 
Table 2: Subgroup analyses where cognition is the outcome of interest at 12 months. Values are 402 
number of participants, mean (standard deviation) unless stated otherwise. 403 
 404 
Figure 1: Bar chart to illustrate the percentage of cohort who demonstrated change in ADAS-Cog score 405 
from baseline to 12 months for usual care and exercise group participants.  406 
 407 
 408 
  409 
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Table 1: Baseline demographic and clinical characteristics of all randomised participants. 
 




Age (years), mean(SD) 78·4 (7·6) 76·9 (7·9) 
Gender (male), n (%) 106 (64·2%) 195 (59·3%) 
Living arrangements, n (%)   
Live alone 35 (21·2%) 62 (18·8%) 
Live with relatives/partner/friends 130 (78·8%) 267 (81·2%) 
Total number of medications taken, mean(SD) 5·5 (3·1) 5·7 (3·7) 
ADAS-Cog, mean(SD) 21·8 (7·7) 21·4 (9.6) 
Language subscale, median (IQR) 2 ( 1 to 4) 2  (0 to 4) 
Memory subscale, mean(SD) 17·4 (4·8) 16·7 (6·2) 
Praxis subscale, median (IQR) 1 (1 to 2) 1  (1 to 2) 
sMMSE, mean(SD) 21·6 (4·6) 22·0 (4·7) 
sMMSE catagorised, n (%)   
No cognitive impairment (24-30) 70 (42.4%) 142 (43.2%) 
Mild cognitive impairment (19-23) 53 (32.1%) 110 (33.4%) 
Moderate cognitive impairment (10-18) 42 (25.5%) 77 (23.4%) 
EQ-5D-3L (self-reported), mean(SD) 0·85 (0·18) 0·82 (0·20) 
QoL-AD (self-reported), mean(SD) 39·3 (5·2) 38·7 (5·6) 
NPI (proxy-reported), median (IQR) 10 (3 to 20) 7.5 (3 to 17.5) 
BADL (proxy-report), median (IQR) 10 (5 to 16) 11  (6 to 17) 
ZBI, mean(SD) 29·0 (15.7) 30·6 (15·4) 
Carer EQ-5D-3L, mean(SD) 0·82 (0·23) 0·79 (0·21) 
 
ADAS-Cog - Alzheimer Disease Assessment Scale cognitive sub-scale; BADL – Bristol Activities of Daily Living 
index; IQR – inter-quartile range; NPI – neuropsychological index; QOL-AD - Quality of Life Alzheimer’s Disease; 
sd – standard deviation; sMMSE - standardised mini-mental state examination score; ZBI - Zarit Burden 
Interview
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Table 2: Subgroup analyses where the change in cognition from baseline to 12 months is the outcome of interest. 
 
Variable 




(95% CI); P-value 
CACE analysis* 
Interaction effect 
(95% CI); P-value Baseline 12 months Baseline 12 months 
Age (years) 
≤78 67; 21.9 (8.8) 59; 25.2 (12.3) 173; 21.5 (10.2) 147; 25.9 (13.7) -0.8 (-2.67, 0.95) -0.9 (-3.35, 1.62); 
0.49 
-1.1 (-4.59, 2.43); 
0.55 
>78 96; 21.7 (6.8) 78; 22.8 (8.6) 156; 21.4 (8.9) 131; 24.5 (10.6) -1.7 (-3.41, -0.04) 
Living 
arrangements 
Live alone 34; 19.4 (7.3) 29; 21.0 (9.1) 62; 19.3 (8.0) 46; 20.9 (9.8) -0.3 (-3.10, 2.48) -1.3 (-4.39, 1.81); 
0.42 
-1.8 (-6.80, 3.20); 
0.48 Live with 
others 129; 22.4 (7.7) 108; 24.6 (10.6) 267; 21.9 (9.9) 232; 26.1 (12.6) -1.6 (-2.96, -0.24) 
Total number of 
medications 
≤4 62; 20.4 (6.4) 51; 22.0 (8.1) 142; 22.7 (9.9) 124; 26.5 (12.9) -1.4 (-3.41, 0.52) 0.2 (-2.34, 2.83); 
0.85 
0.2 (-3.50, 3.75); 
0.95 
>4 92; 22.5 (8.6) 78; 25.0 (11.9) 176; 20.2 (9.1) 146; 24.1 (11.8) -1.2 (-2.86, 0.46) 
ADAS-Cog 
≤20 74; 15.5 (3.1) 67; 18.2 (6.6) 170; 14.0 (3.6) 144; 16.8 (6.3) -0.3 (-2.05, 1.39) -2.1 (-4.53, 0.38); 
0.10 
-2.5 (-5.99, 1.09); 
0.17 
>20 89; 27.0 (6.4) 68; 29.4 (10.6) 159; 29.4 (7.4) 134; 34.3 (10.7) -2.4 (-4.16, -0.66) 
Language subscale 
≤2 96; 17.5 (4.3) 83; 19.3 (6.9) 201; 16.4 (5.9) 173; 19.5 (8.3) -1.0 (-2.55, 0.60) -1.1 (-3.66, 1.41); 
0.39 
-1.3 (-4.78, 2.21); 
0.47 
>2 67; 27.9 (7.3) 54; 30.9 (10.9) 128; 29.3 (9.0) 105; 34.7 (12.0) -2.1 (-4.07, -0.12) 
Memory subscale 
≤17 78; 16.1 (3.9) 72; 19.0 (7.0) 187; 15.0 (4.7) 156; 18.3 (8.3) -0.9 (-2.58, 0.73) -0.9 (-3.41, 1.52); 
0.45 
-1.1 (-4.61, 2.39); 
0.53 
>17 85; 26.9 (6.6) 63; 29.3 (11.0) 142; 29.9 (7.7) 122; 34.1 (10.8) -1.8 (-3.67, -0.06) 
Praxis subscale 
≤1 89; 18.5 (6.1) 79; 19.9 (7.6) 175; 16.4 (6.4) 153; 18.8 (8.5) -0.8 (-2.48, 0.77) -1.2 (-3.62, 1.31); 
0.36 
-1.7 (-5.25, 1.80); 
0.34 
>1 74; 25.7 (7.6) 58; 29.2 (11.4) 154; 27.1 (9.4) 125; 33.1 (11.8) -2.0 (-3.86, -0.16) 
Number 
cancellation 
≤3 95; 18.6 (5.7) 84; 20.3 (8.1) 186; 17.7 (7.4) 165; 19.9 (9.3) -0.3 (-1.86, 1.24) -2.7 (-5.14, -0.21); 
0.03 
-3.7 (-7.23, -0.21); 
0.04 
>3 68; 26.2 (7.9) 53; 29.4 (11.2) 143; 26.3 (10.0) 113; 32.9 (12.2) -3.0 (-4.89, -1.07) 
EQ-5D-3L (self-
reported) 
≤0.848 66; 22.0 (8.0) 55; 23.6 (11.6) 156; 20.2 (9.3) 121; 24.0 (11.8) -1.9 (-3.80, 0.07) 0.9 (-1.62, 3.42); 
0.49 
1.6 (-2.10, 5.24); 
0.40 
>0.848 91; 21.3 (7.4) 79; 24.0 (9.7) 171; 22.4 (9.5) 157; 26.1 (12.7) -1.0 (-2.58, 0.65) 
QoL-AD (self-
reported) 
≤39 61; 22.4 (8.0) 52; 24.8 (12.2) 162; 20.5 (9.3) 133; 24.0 (12.0) -1.2 (-3.12, 0.71) -0.6 (-3.24, 2.10); 
0.68 
-0.7 (-4.52, 3.04); 
0.70 
>39 78; 21.2 (7.1) 66; 22.9 (9.0) 122; 22.2 (9.4) 110; 25.9 (12.1) -1.8 (-3.62, 0.06) 





65; 22.4 (8.2) 56; 23.6 (10.0) 109; 22.6 (10.4) 95; 27.3 (12.6) -2.6 (-4.64, -0.53) 
-2.0 (-4.96, 0.89); 
0.17 




≤11 81; 19.4 (6.3) 72; 21.3 (8.7) 155; 18.6 (7.4) 135; 22.1 (10.9) -1.1 (-2.82, 0.67) -1.1 (-3.83, 1.65); 
0.44 
-1.9 (-5.80, 1.96); 
0.33 
>11 60; 25.3 (8.1) 48; 28.2 (11.3) 132; 25.8 (10.6) 107; 31.1 (12.6) -2.2 (-4.27, -0.06) 
Values are number of participants, mean (standard deviation) unless stated otherwise.  
* - 214 participants were classified as compliers.  
ADAS-Cog - Alzheimer Disease Assessment Scale cognitive sub-scale; BADL – Bristol Activities of Daily Living Index; IQR – inter-quartile range; NPI – neuropsychological 
index; QOL-AD - Quality of Life Alzheimer’s Disease; sd – standard deviation 
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Figure 1: Bar chart to illustrate the percentage of cohort who demonstrated change in ADAS-Cog score from baseline to 12 months for usual care and 
exercise group participants.  
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